Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD)
Study design for the Phase 2 Gladiolus Study of etavopivat in patients with transfusion-dependent (TD) SCD or non-TD/TD thalassemia
Forma’s accepted presentations cover updated results from the open-label extension cohort of the completed Phase 1 study of etavopivat, including an analysis of the frequency and severity of pain-related adverse events, as well as the study design and key enrollment criteria of the Phase 2 Gladiolus Study of etavopivat in TD SCD, non-TD thalassemia and TD thalassemia.
“We believe that data from our Phase 1 study support a highly differentiated etavopivat profile that can potentially improve the lives of patients with SCD by increasing hemoglobin levels, improving red blood cell health, and decreasing vaso-occlusive crises,” said
Details of the Forma-led abstracts are below. The EHA abstracts are also currently available online.
EHA Poster Presentation
Abstract #P1495: Etavopivat Treatment for up to 12 Weeks in Patients with Sickle Cell Disease Was Well Tolerated and Improved Red Blood Cell Health
Abstract #PB2232: Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the Erythrocyte Pyruvate Kinase Activator Etavopivat in Patients with Thalassemia or Sickle Cell Disease
FSCDR Oral Presentations
Presenting Author (Virtual):
Abstract #1212753: Trial in Progress: The Gladiolus Study, a Phase 2, Open-Label Trial Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease
Presenting Author (Virtual):
GCSCD Oral Presentation
Abstract #A34775TM: Etavopivat Treatment for up to 12 Weeks in Patients with
GCSCD Poster Presentation
Abstract #A34785TC: Trial in Progress: The Gladiolus Study, A Phase 2, Open-Label Trial Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the company’s beliefs and expectations regarding its: planned presentations at EHA, FSCDR and GCSCD; business plans and objectives; future plans for etavopivat , including expectations regarding potential development expansion plans as well as the enrollment, timing, success and data announcements of planned and ongoing clinical trials; therapeutic potential, clinical benefits, mechanisms of action and safety of our product candidates; upcoming milestones and planned additional trials for the company’s product candidates; growth as a company; and the potential impact of COVID-19 on patient retention and enrollment, future operations or clinical trials. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties associated with the following: the impact of the COVID-19 pandemic on the company’s business, operations, supply chain, patient enrollment and retention, clinical trials, strategy, goals and anticipated milestones, as well as global economies and financial markets; the therapeutic potential of our product candidates and the timing and completion of our clinical trials and related data analyses; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; any one or more of our product candidates may not be successfully developed and commercialized; regulatory developments in
Kendall Investor Relations